Karman Holdings: 26% Drop Creates Opportunity, But Not Quite A Buy Yet

Q4 sales rose 47% and full-year sales rose 37%, with margin expansion and strong contributions from recent acquisitions. 2026 guidance points to further revenue growth but margin contraction and EBITDA growth lagging sales due to capacity expansion and inorganic growth, indicating top-line momentum but near-term margin pressure.

Analysis

Karman sits at an inflection point where sector-specific capacity builds—not just topline growth—will determine who captures durable margin. Expect upward pressure on specialty inputs (titanium, high-grade composites, precision CNC capacity) and test-range time across the next 6–18 months; these input bottlenecks will transmit as transitory margin compression even if bookings stay strong. That dynamic benefits upstream niche suppliers and testing/logistics providers while compressing peer margins where scale and long lead-time tooling matter.

The most important operational drag is working-capital and integration dilution from inorganic growth: acquisitive roll-ups typically show EBITDA lag for 9–24 months while shop-floor yields and common systems are harmonized. Policy and program-level catalysts (DoD funding reauthorization, OTAs converting to IDIQs, export approvals) create 3–12 month binary moments that can both accelerate backlog conversion or abruptly pause procurement; program cancellations or reprioritization are 12–36 month tail risks. Interest-rate sensitivity is second-order but real: debt-funded capacity builds amplify EBIT sensitivity to rates when synergies slip.

Positioning should be time-layered. Trade around near-term volatility from guidance updates and earnings prints, but keep a 12–24 month horizon for scalability and FCF conversion. The market is likely underpricing the capacity/delivery execution risk now, so asymmetric option structures that cap downside while leaving upside uncapped through late-2026 expiries are preferable to outright levered equity exposure.

Key Decisions for Investors

• Long KRMN via a 12–18 month call spread: buy LEAP ~20–25% OTM call, sell a nearer-term 6–9 month call to finance ~50–70% of cost. Timeframe: 12–18 months. R/R: target 40–60% equity upside if integration-driven margin recovery occurs; downside limited to premium paid (~100% loss of premium).
• Pair trade (sector growth vs prime stability): long KRMN equal notional / short LMT (Lockheed Martin) for 12 months. Timeframe: 6–12 months. R/R: captures rerating if small-cap hypersonics share gains accelerate ~30–50%; risk is primes win large awards and compress spread—cap loss ~15–25% on notional.
• Short-duration hedge around next quarter: buy 3-month 8–12% OTM puts on KRMN into next earnings/guidance window. Timeframe: days–weeks. R/R: pays off on a downside surprise or missed integration milestones; cost small relative to equity exposure (~0.5–2% of position size).
• Rotation into suppliers: modest long position in specialized-materials and testing providers (e.g., HXL, LHX) for 6–18 months. Timeframe: 6–18 months. R/R: beneficiary of input price inflation and test-capacity scarcity; expected 15–30% upside if sector ramps, with single-digit downside tied to broader defense drawdowns.